Literature DB >> 12578987

Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding.

Marco Cattaneo1, Maddalena L Zighetti, Rossana Lombardi, Constantino Martinez, Anna Lecchi, Pamela B Conley, Jerry Ware, Zaverio M Ruggeri.   

Abstract

We have identified structural attributes required for signal transduction through a seven-transmembrane-domain receptor. Platelets from a patient (AC) with a congenital bleeding disorder had normal shape change but reduced and reversible aggregation in response to 4 microM ADP, similar to normal platelets with blocked P2Y(12) receptor. The response to 20 microM ADP, albeit still decreased, was more pronounced and was reduced by a P2Y(12) antagonist, indicating some residual receptor function. ADP failed to lower the adenylyl cyclase activity stimulated by prostaglandin E(1) in the patient's platelets, even though the number and affinity of 2-methylthioadenosine 5'-[(33)P]diphosphate-binding sites was normal. Analysis of the patient's P2Y(12) gene revealed a G-to-A transition in one allele, changing the codon for Arg-256 in the sixth transmembrane domain to Gln, and a C-to-T transition in the other allele, changing the codon for Arg-265 in the third extracellular loop to Trp. Neither mutation interfered with receptor surface expression but both altered function, since ADP inhibited the forskolin-induced increase of cAMP markedly less in cells transfected with either mutant P2Y(12) as compared with wild-type receptor. These studies delineate a region of P2Y(12) required for normal function after ADP binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578987      PMCID: PMC149944          DOI: 10.1073/pnas.0437879100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Homologous mutations near the junction of the sixth transmembrane domain and the third extracellular loop lead to constitutive activity and enhanced agonist affinity at all muscarinic receptor subtypes.

Authors:  Diane J Ford; Anthony Essex; Tracy A Spalding; Ethan S Burstein; John Ellis
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

Review 2.  A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism.

Authors:  Y Inoue; N Nakamura; T Inagami
Journal:  J Hypertens       Date:  1997-07       Impact factor: 4.844

3.  Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin.

Authors:  D L Farrens; C Altenbach; K Yang; W L Hubbell; H G Khorana
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

4.  Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production.

Authors:  M Cattaneo; R Lombardi; M L Zighetti; C Gachet; P Ohlmann; J P Cazenave; P M Mannucci
Journal:  Thromb Haemost       Date:  1997-05       Impact factor: 5.249

5.  Preparation of suspensions of washed platelets from humans.

Authors:  J F Mustard; D W Perry; N G Ardlie; M A Packham
Journal:  Br J Haematol       Date:  1972-02       Impact factor: 6.998

6.  Identification of a receptor/G-protein contact site critical for signaling specificity and G-protein activation.

Authors:  J Liu; B R Conklin; N Blin; J Yun; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

8.  An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.

Authors:  P Nurden; P Savi; E Heilmann; C Bihour; J M Herbert; J P Maffrand; A Nurden
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.

Authors:  M Cattaneo; A Lecchi; A M Randi; J L McGregor; P M Mannucci
Journal:  Blood       Date:  1992-12-01       Impact factor: 22.113

10.  Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.

Authors:  C Gachet; M Cattaneo; P Ohlmann; B Hechler; A Lecchi; J Chevalier; D Cassel; P M Mannucci; J P Cazenave
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

View more
  37 in total

Review 1.  Central role of the P2Y12 receptor in platelet activation.

Authors:  Robert T Dorsam; Satya P Kunapuli
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 2.  P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.

Authors:  Christian Gachet
Journal:  Purinergic Signal       Date:  2012-04-11       Impact factor: 3.765

3.  Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.

Authors:  Carl Högberg; Olof Gidlöf; Francesca Deflorian; Kenneth A Jacobson; Aliaa Abdelrahman; Christa E Müller; Björn Olde; David Erlinge
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

Review 4.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 6.  P2Y12 receptor: platelet thrombus formation and medical interventions.

Authors:  Fatemeh Moheimani; Denise E Jackson
Journal:  Int J Hematol       Date:  2012-10-01       Impact factor: 2.490

7.  P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.

Authors:  Anneke Bierend; Thomas Rau; Renke Maas; Edzard Schwedhelm; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

8.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling.

Authors:  Stefano Costanzi; Liaman Mamedova; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

9.  Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12.

Authors:  Philipp Schmidt; Lars Ritscher; Elizabeth N Dong; Thomas Hermsdorf; Maxi Cöster; Doreen Wittkopf; Jens Meiler; Torsten Schöneberg
Journal:  Mol Pharmacol       Date:  2012-10-23       Impact factor: 4.436

Review 10.  Inherited platelet disorders: thrombocytopenias and thrombocytopathies.

Authors:  Giovanna D'Andrea; Massimiliano Chetta; Maurizio Margaglione
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.